Table 2.

Demographic factors, clinical characteristics, chemotherapy regimen, response assessment, and time intervals of imaging follow-up of patients analyzed with serial PET/CT studies

ID	Sex	Age	Pathology	Staging	Chemotherapy	No. of cycles	Response to therapy	Time (baseline − follow-up imaging) (in days)	Time (end of chemotherapy to follow-up imaging) (in days)	Memory problems and/or depression1
1	M	59	NSCLC	IIIb	Carboplatin/taxol2	3	PR
					Carboplatin/gemcitabine/avastin	3	PR	230	5	?
2	F	64	NSCLC	IIIb	Cisplatin/etoposide	1	SD	111	11	?
3	M	48	NSCLC	IIIb	Carboplatin/taxol	3	PR	81	5	?
4	M	64	NSCLC	IIIb	Cisplatin/gemcitabine	3	PD	311	28	Yes
					Cisplatin/navelbine	4	SD
5	M	71	NSCLC	IIIa	Carboplatin/taxol	4	PD
					Alimta (pemetrexed)	2	SD	402	10	Yes
6	M	63	NSCLC	IIIb	Carboplatin/taxol	4	PD	88	10	Yes
7	F	74	NSCLC	IIIa	Cisplatin/etoposide	2	PR	132	22	Yes
8	M	58	NSCLC	IIIb	Carboplatin/taxol/ avastin	2	PD
					Alimta	2	PD	142	2	?
9	M	78	NSCLC	IIIb	Carboplatin/taxol	4	PR	171	13	Yes
10	F	46	NSCLC	IV	Carboplatin/taxol/ avastin	4	PD	140	8	Yes

PR, partial response; SD, stable disease; PD, progressive disease.

¹Memory disturbance and mood alterations were assessed based on subjective patient reports and evidence in the patient’s interval history.

²Patient had a partial response, however, developed intolerance/allergy to taxol; therefore, treatment was changed to carboplatin/gemcitabine/avastin.